Globally Roche has more than 2,500 scientists working in Pharma Research centres around the world who are passionate about discovering medicines to meet the unmet medical needs of patients. We also have 4,000 scientists and physicians engaged in Pharma Development projects globally. This group designs and conducts pre-clinical and clinical trials to transform promising compounds into clinically differentiated medicines for patients.
Areas of global research we engage in include:
• Central Nervous System
Our R&D sites include:
|Basel, Switzerland (R&D)||Central Nervous System and Metabolics|
|Kulmbach Germany (R)||RNA-based Therapeutics|
|Madison (WI), USA (R)||RNA Interference|
|Nutley (NJ), USA (R&D)||Inflammation, Oncology and Virology|
|Penzberg, Germany (R)||Protein Therapeutics|
|Schlieren, Switzerland (R)||Antibody Engineering|
|Shanghai, China (R&D)||Research and Clinical Development|
|South San Francisco (R&D)||Oncology, Immunology, Tissue Growth and Repair|
|Disorders, Neuroscience, and Infectious Disease|
|Sydney, Australia (D)||Clinical Development Operations|
|Welwyn, United Kingdom (D)||Pharmaceutical Development|
Clinical Research in Canada
For more than two decades, our Clinical Research Group has played a pivotal role in Roche's global development programs for new medicines. Roche Canada is a leader in the Roche world in clinical trial recruitment. We have also worked extensively with physicians, healthcare institutions and CRO (contract research organization) partners to advance healthcare opportunities for Canadians in areas such as oncology and rheumatoid arthritis.
In 2009, Roche invested approximately $9.1 million in Canada towards the development of therapies through clinical trials. Roche currently has more than 100 clinical trials in Canada with over 3,600 patients enrolled.
For more information on global pharmaceuticals R&D, please click here to visit our global Web site